Mtx Ratiopharm (Methotrexate)

Methotrexate blocks the enzyme dihydrofolate reductase, preventing the formation of tetrahydrofolate needed for DNA, RNA and protein synthesis. This inhibition reduces the proliferation of rapidly dividing cells, including immune cells that drive inflammation and cancer cells that require DNA replication. It also promotes the release of anti‑inflammatory adenosine.

The specific dose of Mtx Ratiopharm is determined by the prescribing clinician based on the patient’s condition, weight, renal function and treatment goals. Dosage regimens vary widely between indications such as rheumatoid arthritis, psoriasis or oncology, and should always follow the prescriber’s written instructions.

Methotrexate is classified as Pregnancy Category X, meaning it is contraindicated in pregnancy due to a high risk of fetal malformations and miscarriage. It is also not recommended while breastfeeding because it can be excreted in milk and may harm the infant. Effective contraception is required during treatment and for a period after discontinuation.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain logistics if needed) and the necessary import documentation.

Methotrexate is a folate antagonist, distinct from calcineurin inhibitors (e.g., cyclosporine) or biologic agents (e.g., TNF‑alpha blockers). It is generally less expensive and has a well‑established efficacy profile for rheumatoid arthritis and psoriasis, but may require more laboratory monitoring for liver and bone‑marrow toxicity compared with some newer biologics.

Mtx Ratiopharm should be stored at 2‑8 °C, protected from light, and kept in its original packaging to maintain stability. Do not freeze or shake the vial. If the product reaches room temperature for a short period, it may be used promptly, but prolonged exposure should be avoided.

Mtx Ratiopharm is supplied for subcutaneous injection. The injection is typically given by a healthcare professional or trained patient using a sterile needle and syringe, following aseptic technique. The injection site is rotated to minimize local irritation, and the dose is administered according to the prescriber’s schedule.

The most serious risks include severe hepatotoxicity, bone‑marrow suppression leading to pancytopenia, pulmonary toxicity such as interstitial pneumonitis, and renal impairment. Patients should be monitored regularly with liver function tests, complete blood counts and renal function assessments, and any signs of infection or respiratory symptoms should prompt immediate medical evaluation.

Methotrexate is contraindicated in pregnant women, patients with severe liver disease, uncontrolled infections, significant renal impairment (creatinine clearance <30 mL/min), and those with known hypersensitivity to methotrexate or any of its excipients. Caution is also advised for patients with a history of pulmonary disease or alcohol misuse.